Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines

The breast cancer (BC) biomarker HER2 (Human Epidermal Receptor 2) is overexpressed in 25% of BC. Only patients with HER2-positive tumors receive HER2-targeting therapies, like trastuzumab (Herceptin). However, some women with a HER2-negative BC could benefit from trastuzumab. This could be explaine...

Descripción completa

Detalles Bibliográficos
Autores principales: Burguin, Anna, Furrer, Daniela, Ouellette, Geneviève, Jacob, Simon, Diorio, Caroline, Durocher, Francine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316326/
https://www.ncbi.nlm.nih.gov/pubmed/32584853
http://dx.doi.org/10.1371/journal.pone.0234991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316326/
https://www.ncbi.nlm.nih.gov/pubmed/32584853
http://dx.doi.org/10.1371/journal.pone.0234991

Ejemplares similares